OS Therapies heading to FDA with positive osteosarcoma data

Shares of OS Therapies Inc. (NYSE-A:OSTX) jumped more than 10% in morning trading after the company reported positive phase IIb data, showing OST-HER2, an immunotherapy approach comprising the HER2/neu antigen expressed by an attenuated Listeria monocytogenes vector, hit the primary endpoint of 12-month event-free survival (EFS), preventing recurrence in fully resected, lung metastatic osteosarcoma patients. Data also showed strong trends in overall survival, with all patients who achieved the EFS endpoint remaining alive as of data cutoff. With those results in hand, OS plans to meet with the U.S. FDA regarding an accelerated approval filing for…